Fundraising Fox

Draig Therapeutics

Cardiff, GB · 44 employees on LinkedIn · 9 known investors

Find your way into Draig Therapeutics

287 people in our graph share verified history with the Draig Therapeutics team — schools, employers, funds. One of them is your warm intro.

Sam Blackmanunlockedknows Simon Ward · together at GlaxoSmithKline (overlapped)
×2knows the team · via University of Sussex
×7knows the team · via University of Cambridge
×2knows the team · via GlaxoSmithKline

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders. The company was founded by Cardiff University and SV Health Investors in 2024.

Founders & leadership

JA
John AtackinHead of Biology & Founder
SWSimon Ward
Simon WardinChief Scientific Officer & FounderSimon Ward is a neuroscience researcher with over 25 years of experience in pharmaceutical, biotech, and academic settings. He holds a Sêr Cymru Professorship in Translational Drug Discovery at Cardiff University, where he founded the Medicines Discovery Institute, and is Founder and Chief Scientific Officer of Draig Therapeutics, a clinical-stage biotech company developing neuropsychiatric therapies.

Investors · 9

Also in the syndicate · 2

Deep Track CapitalleadJefferson Life Sciences

Funding

SEC filings, press & company announcements

$65M disclosed across 1 round · 2026

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗
Registered name
DRAIG THERAPEUTICS LTD
Company number
13405365
Status
Active
Company type
Private limited company
Incorporated
18 May 2021
Registered office
Sbarc Spark, Maindy Road, Cardiff, CF24 4HQ
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 17 May 2026 · next due 31 May 2027

Current officers · 9

  • Samantha Louise Budd Haeberlein director, appointed 5 Sept 2024
  • Colleen Cuffaro director, appointed 10 Jun 2025
  • Charles Montfort Dunn director, appointed 5 Sept 2024
  • Ivana Magovcevic-Liebisch director, appointed 10 Nov 2025
  • Ruth Mitchell Mckernan director, appointed 5 Sept 2024
  • Jodie Pope Morrison director, appointed 17 Mar 2026
  • Liam Ratcliffe director, appointed 10 Jun 2025
  • Laetitia Schwab director, appointed 10 Jun 2025
  • Douglas Edward Williams director, appointed 10 Jul 2025

Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Frequently asked questions

What does Draig Therapeutics do?
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders. The company was founded by Cardiff University and SV Health Investors in 2024.
Who founded Draig Therapeutics?
Draig Therapeutics was founded by John Atack, Simon Ward.
Who are Draig Therapeutics's investors?
Draig Therapeutics's investors include Access Biotechnology, Canaan Partners, Sanofi Ventures, SV Health Investors, SR One Capital Management, British Business Bank, Janus Henderson Investors.
How much funding has Draig Therapeutics raised?
Draig Therapeutics has disclosed $65M raised across 1 round.
Where is Draig Therapeutics headquartered?
Draig Therapeutics is headquartered in Cardiff, GB.